An excellent guide on the clinical management of key adverse events associated with sacituzumab govitecan. Sacituzumab govitecan is highly effective but requires proactive AE management. Sara Tolaney Hope Rugo OncoAlert LARVOL

Updated Guideline on Postmastectomy Radiation Therapy (PMRT)! ASCO, ASTRO & SSO have released new evidence-based recommendations. 🔹 Who benefits? Node-positive patients: PMRT recommended. High-risk node-negative patients: Consider PMRT (large tumors, young age) After

Tumor agnostic precision oncology!!!! ROME trial (phase II) in advanced solid tumors: ✅ORR ↑ 17.5% vs. 10% ✅Median PFS 3.5 vs. 2.8 mo (HR 0.66, p=0.0002) ✅12-mo PFS 22% vs. 8.3% ❓OS: no difference (high 59% crossover) G Curigliano MD PhD ESMO - Eur. Oncology OncoAlert nature LARVOL

The incidence of early-onset GI cancer is rising globally, especially in high-income countries. JAMA Network

Young #breastcancer survivors (≤40 yrs) often stay tied to oncology for follow-up !!! ✅ 82% got mammograms ⬇️ Only 42% (ET users) had bone density scans ⬇️ Preventive care (flu shots, cholesterol screening) lagged Strong cancer surveillance, but gaps in general health care

Top #BreastCancer Oncologists for Q3 2025, curated by LARVOL CLIN. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights #ClinicalTrials | Yakup Ergün |

FDA Approves Lurbinectedin/Atezolizumab Maintenance in ES-SCLC  based on IMforte results! 🔹 Median PFS: 5.4 vs 2.1 mo (HR 0.54, p<.0001) 🔹 OS: 13.2 vs 10.6 mo (HR 0.73, p=.017) 🔹 12-mo OS: 56% vs 44% LARVOL OncoAlert U.S. FDA

At the Eurasian Interdisciplinary Oncology Congress, we discussed modern approaches for patients with oligometastatic breast cancer. Collaboration & knowledge-sharing are essential to improve care. #Oncology #BreastCancer #EurasianOncology OncoDaily

New 10-year data from the PORTEC-3 trial sheds light on optimal adjuvant therapy for high-risk endometrial cancer. 👉 Chemoradiotherapy vs. radiotherapy alone. Published in The Lancet Oncology (2025). #EndometrialCancer #Oncology #ClinicalTrials OncLive.com OncoDaily OncoAlert

PORTEC-3 : CRT vs Rt in high-risk endometrial cancer 10-year clinical outcomes and post-hoc analysis by molecular classification! • 10-year OS: 74.4% vs 67.3% (HR 0.73, p=0.032) • 10-year RFS: 72.8% vs 67.4% (HR 0.74, p=0.034) 💡 Greatest survival benefit seen in p53-abnormal

10-year results from PORTEC-3 show that adjuvant CRT improves OS & RFS vs RT alone in high-risk endometrial cancer! ✅p53-abn: OS 52.7% vs 36.6% → HR 0.52 (p=0.021) RFS 52.6% vs 37.0% → HR 0.42 (p=0.0027) ✅MMRd: no clear benefit from CRT ✅POLEmut: excellent survival

DATROWAY trial update: Datopotamab Deruxtecan (Dato-DXd) hits both OS & PFS endpoints in 1L mTNBC (IO-ineligible) — first ADC to do so! A new era for TROP2-directed therapy begins. #TNBC #Oncology #ESMO25 #DatoDXd #ADC

FDA Approval Alert (Oct 8, 2025): FDA approves cemiplimab-rwlc (Libtayo) for adjuvant treatment of cutaneous SCC at high risk of recurrence after surgery & radiation. Cemiplimab cut recurrence risk by 68% (HR 0.32; p<0.0001). ⁦LARVOL⁩ fda.gov/drugs/resource…

Long-term results from DESTINY-Breast04 Nature Medicine After 32 mo follow-up, T-DXd shows durable OS benefit in HER2-low mBC: ✅OS 22.9 vs 16.8 mo (HR 0.69) ✅HR+ 23.9 vs 17.6 mo ✅PFS 8.8 vs 4.2 mo #BreastCancer #Oncology #TDXd #DESTINYBreast04 @larvol OncoAlert OncoDaily

Women with high PRS313 after in situ breast disease face far higher risks: ➡️ DCIS → 2× contralateral events ➡️ LCIS → 2–4× ipsilateral invasive recurrence Long-term follow-up (11 yrs, n = 2,300) shows genetics can refine surveillance & prevention. #BreastCancer

Missing even one mammography round matters! In a Swedish cohort of 8,602 screen-detected breast cancers, skipping the prior screening was linked to: ⬆️ Larger tumors, nodal mets, worse survival. Early, regular screening saves lives. jamanetwork.com/journals/jaman… JAMA Network LARVOL

The DESTINY-Breast11 trial (DB-11) just dropped: T-DXd+THP beats ddAC-THP in high-risk HER2+ eBC with higher pCR and lower toxicity. This could mark a true paradigm shift — moving away from anthracycline-based regimens in high-risk HER2+ early breast cancer. #BreastCancer

New nationwide data (Wolswinkel et al., JCO Oncol Pract, 2025) show that fertility-sparing surgery in early-stage cervical cancer carries a slightly higher recurrence risk, but no difference in OS. With modern and personalized treatments, our patients live longer than ever — yet